The path of anti-tuberculosis drugs: From blood to lesions to mycobacterial cells

Research output: Contribution to journalArticlepeer-review

226 Scopus citations

Abstract

For the successful treatment of pulmonary tuberculosis, drugs need to penetrate complex lung lesions and permeate the mycobacterial cell wall in order to reach their intracellular targets. However, most currently used anti-tuberculosis drugs were introduced into clinical use without considering the pharmacokinetic and pharmacodynamic properties that influence drug distribution, and this has contributed to the long duration and limited success of current therapies. In this Progress article, I describe new methods to quantify and image drug distribution in infected lung tissue and in mycobacterial cells, and I explore how this technology could be used to design optimized multidrug regimens.

Original languageEnglish (US)
Pages (from-to)159-167
Number of pages9
JournalNature Reviews Microbiology
Volume12
Issue number3
DOIs
StatePublished - Mar 2014

All Science Journal Classification (ASJC) codes

  • Microbiology
  • Immunology and Microbiology(all)
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'The path of anti-tuberculosis drugs: From blood to lesions to mycobacterial cells'. Together they form a unique fingerprint.

Cite this